Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Y Brandberg; S Aamdal; Lars Bastholt; M Hernberg; U Stierner; H von der Maase; Johan Hansson

doi:10.1016/j.ejca.2011.11.019

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Y Brandberg, S Aamdal, Lars Bastholt, M Hernberg, U Stierner, H von der Maase, Johan Hansson

26 Citations (Scopus)

Abstract

To compare health-related quality of life (HRQoL) and side-effects in patients with high-risk melanoma participating in a randomised phase III trial of adjuvant interferon alfa-2b (IFN).

Original language	English
Journal	European Journal of Cancer
Volume	48
Issue number	13
Pages (from-to)	2012-9
Number of pages	8
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2011.11.019
Publication status	Published - 2012

Keywords

Adolescent
Adult
Aged
Chemotherapy, Adjuvant
Female
Humans
Interferon-alpha
Male
Melanoma
Middle Aged
Quality of Life
Recombinant Proteins
Risk
Skin Neoplasms
Young Adult

Access to Document

10.1016/j.ejca.2011.11.019

Cite this

@article{b9785a3e193b4313b9cfec34ba3008ee,

title = "Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b",

abstract = "To compare health-related quality of life (HRQoL) and side-effects in patients with high-risk melanoma participating in a randomised phase III trial of adjuvant interferon alfa-2b (IFN).",

keywords = "Adolescent, Adult, Aged, Chemotherapy, Adjuvant, Female, Humans, Interferon-alpha, Male, Melanoma, Middle Aged, Quality of Life, Recombinant Proteins, Risk, Skin Neoplasms, Young Adult",

author = "Y Brandberg and S Aamdal and Lars Bastholt and M Hernberg and U Stierner and \{von der Maase\}, H and Johan Hansson",

year = "2012",

doi = "10.1016/j.ejca.2011.11.019",

language = "English",

volume = "48",

pages = "2012--9",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "13",

}

TY - JOUR

T1 - Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

AU - Brandberg, Y

AU - Aamdal, S

AU - Bastholt, Lars

AU - Hernberg, M

AU - Stierner, U

AU - von der Maase, H

AU - Hansson, Johan

PY - 2012

Y1 - 2012

N2 - To compare health-related quality of life (HRQoL) and side-effects in patients with high-risk melanoma participating in a randomised phase III trial of adjuvant interferon alfa-2b (IFN).

AB - To compare health-related quality of life (HRQoL) and side-effects in patients with high-risk melanoma participating in a randomised phase III trial of adjuvant interferon alfa-2b (IFN).

KW - Adolescent

KW - Adult

KW - Aged

KW - Chemotherapy, Adjuvant

KW - Female

KW - Humans

KW - Interferon-alpha

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Quality of Life

KW - Recombinant Proteins

KW - Risk

KW - Skin Neoplasms

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84865109234

U2 - 10.1016/j.ejca.2011.11.019

DO - 10.1016/j.ejca.2011.11.019

M3 - Journal article

C2 - 22196968

SN - 0959-8049

VL - 48

SP - 2012

EP - 2019

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 13

ER -

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this